2018-11-25 12:37:00 Sun ET
technology antitrust competition bilateral trade free trade fair trade trade agreement trade surplus trade deficit multilateralism neoliberalism world trade organization regulation public utility current account compliance
The Chinese administration delivers a written response to U.S. demands for trade reforms. This strategic move helps trigger more formal negotiations between both sides to resolve the current Sino-American trade war. Thus far $360 billion Chinese imports have been subject to 10%-25% U.S. tariffs, and the Trump administration floats additional duties and concessions in recent times. In light of the U.S. midterm elections, President Trump expects to strike a positive trade deal with China. The Trump administration is thus unlikely to impose new tariffs on Chinese imports. As both Chinese and American delegates and diplomats resume their trade talks, the Trump team now sidelines most diehard protectionists.
President Trump and Chinese President Xi can next meet to agree on a new trade framework at the G20 summit in late-November 2018. China can purchase more American goods to help lower bilateral U.S. trade deficits. Nevertheless, the Trump administration may find it difficult to prevent the perennial Sino-U.S. technology transfer and other intellectual property theft in the mainland. This trade dilemma reflects the reality of unfair trade practices in several high-tech industries such as semiconductors, microchips, smart phones, visual animations, speech recognition devices, and artificial intelligence apps etc.
In fact, Sino-American bilateral trade deficits have ballooned about 10% from $275 billion to $305 billion in the interim period from September 2017 to November 2018. Part of this deficit increase reflects an 8.1% surge in U.S. imports from China while U.S. exports to China remain flat. U.S, real output growth, employment, and capital investment fire on all cylinders, thus the American economy attracts more Chinese imports in the current phase of robust economic growth. Greenback appreciation also contributes to this bilateral trade deficit increase, whereas, a weaker Chinese currency helps offset some costs of American tariffs on Chinese imports. The U.S. cannot readily replace Chinese imports with close substitutes because only China can produce these goods in a cost-effective way.
On balance, the Trump administration should seek to deter unfair trade practices such as Sino-American technology transfer and patent and trademark infringement. Whether the Trump team can reduce bilateral trade deficits with China becomes a secondary issue. Insofar as the Trump administration can attain 3%-4% real GDP economic growth, the additional tax revenue intake can self-finance fiscal budget and trade deficits.
If any of our AYA Analytica financial health memos (FHM), blog posts, ebooks, newsletters, and notifications etc, or any other form of online content curation, involves potential copyright concerns, please feel free to contact us at service@ayafintech.network so that we can remove relevant content in response to any such request within a reasonable time frame.
2019-04-07 13:39:00 Sunday ET

CNBC news anchor Becky Quick interviews Warren Buffett in early-2019. Buffett explains the fact that book value fluctuations are a metric that has lost rele
2022-02-25 00:00:00 Friday ET

Empirical tests of multi-factor models for asset return prediction The capital asset pricing model (CAPM) of Sharpe (1964), Lintner (1965), and Bla
2020-10-06 09:31:00 Tuesday ET

Strategic managers envision lofty purposes to enjoy incremental consistent progress over time. Allison Rimm (2015) The joy of strategy: a bu
2019-10-21 10:35:00 Monday ET

American state attorneys general begin bipartisan antitrust investigations into the market power and corporate behavior of central tech titans such as Apple
2019-02-02 11:36:00 Saturday ET

The Trump administration teams up with western allies to bar HuaWei and other Chinese tech firms from building the 5G high-speed infrastructure due to natio
2019-01-10 17:31:00 Thursday ET

The recent Bristol-Myers Squibb acquisition of American Celgene is the $90 billion biggest biotech deal in history. The resultant biopharma goliath would be